Guangdong Hybribio Biotech Co.,Ltd. (SHE:300639)

Market Cap	3.06B -14.2%
Revenue (ttm)	661.41M -13.7%
Net Income	-106.43M
EPS	-0.17
Shares Out	627.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,146,423
Open	4.88
Previous Close	4.88
Day's Range	4.75 - 5.11
52-Week Range	4.87 - 10.07
Beta	0.47
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 26, 2026

About SHE:300639

Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/i...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2003
• Employees: 1,990
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300639

Financial Performance

In 2025, SHE:300639's revenue was 669.64 million, a decrease of -17.89% compared to the previous year's 815.53 million. Losses were -130.94 million, -80.01% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 29, 2026

Data Sources Report a data error